MRI MRCP - Cyst (IPMN) - Newbie

Posted by chasenkw @chasenkw, Jul 12, 2022

So much gratitude for this group. Thank you !

My New GI doctor at University of Miami Healthcare ordered this test after I called needing colonoscopy. I discussed frequent abdominal pain, bloating, and more frequent bouts of pancreatitis. The findings:

Pancreas: Homogeneous parenchymal enhancement with a 0.6 cm cystic lesion in the pancreatic body, likely reflecting a small side branch IPMN. Otherwise, no lesions or ductal dilatation dilatation.

Should there be further testing of these finding? I have not heard from Dr yet. The test was last week, I obtained results from portal. “Is NO news GOOD news?”

Again, many many thanks.
Chase

Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.

I had my distal pancreatectomy on July 29, 2022. The tail end of the pancreas was removed along with the spleen. I was in the hospital for five days. I fully recovered from the surgery with no major complications. When the IPMN was noticed in 2021, I had an EUS performed that revealed benign, no alarming results. So, surgeon decided to scan again in a year, at which time the increase in dilatation was very noticeable. Pathology report after surgery suspected the IPMN might have been involved in the adenocarcinoma found. But, I was lucky that margins were clean, no spread. They removed 16 lymph nodes, all clean. With my stage 1 b diagnosis, I am undergoing chemo. I'm halfway through treatment, and it's not pleasant, but slogging through. I hope this information is helpful to you.

REPLY
@ken240

I had a 2cm MD-IPMN from scan in 2021. Scan in 2022 showed cyst was 2.1 cm, but duct was showing signs of dilatation. So, I had distal pancreatectomy done this year. Pathology labeled me as stage 1b.

Jump to this post

Hi, I have a 1.4 cm BD-IPMN and both my main pancreatic duct (6mm) and my common bile duct (15mm) are dilated. I recently was diagnosed with EPI. My doctor hasn’t suggested doing anything other than another EUS but I’m pretty concerned about it based on everything I have read.

How many months ago did you have your surgery? How are you feeling now? I read only a little bit about different procedures based on where the IPMNs are located. They removed part of your pancreas and your spleen?

REPLY
@7judy2

I will read them again but what I meant was that the older guidelines I thought had said to do nothing about IPMNs if they are less than 3 but the newer 2017 guidelines if I remember correctly are saying that if a person also has dilated ducts and or other concerning symptoms then you do do something regardless of the size of the IPMNs. In some cases that could mean just yearly MRIs to follow and in some cases it might mean surgery.

Jump to this post

I had a 2cm MD-IPMN from scan in 2021. Scan in 2022 showed cyst was 2.1 cm, but duct was showing signs of dilatation. So, I had distal pancreatectomy done this year. Pathology labeled me as stage 1b.

REPLY
@7judy2

I will read them again but what I meant was that the older guidelines I thought had said to do nothing about IPMNs if they are less than 3 but the newer 2017 guidelines if I remember correctly are saying that if a person also has dilated ducts and or other concerning symptoms then you do do something regardless of the size of the IPMNs. In some cases that could mean just yearly MRIs to follow and in some cases it might mean surgery.

Jump to this post

Refer to Figure 2 in the 2017 Fukuoka Guidelines link. It is a flow chart that summarizes recommended surveillance frequencies and intervention by size and characteristics.

REPLY
@stageivsurvivor

Those are existing guidelines since 2017. I’m familiar with those as I have referred to them many times. I thought you mentioned you saw newer guidelines. That’s what I am interested in seeing if they exist. As far as I recall, no newer guidelines exist. The Fukuoka guidelines are the most current issued by that working group.

Jump to this post

I apologize for not looking at who you are or what you have been through earlier. I just responded without thinking. I’m sure you have much more information on this than I could possibly have.

REPLY
@stageivsurvivor

Those are existing guidelines since 2017. I’m familiar with those as I have referred to them many times. I thought you mentioned you saw newer guidelines. That’s what I am interested in seeing if they exist. As far as I recall, no newer guidelines exist. The Fukuoka guidelines are the most current issued by that working group.

Jump to this post

I will read them again but what I meant was that the older guidelines I thought had said to do nothing about IPMNs if they are less than 3 but the newer 2017 guidelines if I remember correctly are saying that if a person also has dilated ducts and or other concerning symptoms then you do do something regardless of the size of the IPMNs. In some cases that could mean just yearly MRIs to follow and in some cases it might mean surgery.

REPLY

Here is the link to the 2017 Fukuoka IPMN Management guidelines also available as a pdf file from the same link.
https://www.sciencedirect.com/science/article/pii/S1424390317305161

REPLY
@7judy2

Fukuoka guidelines for IPMNs in 2017

Jump to this post

Those are existing guidelines since 2017. I’m familiar with those as I have referred to them many times. I thought you mentioned you saw newer guidelines. That’s what I am interested in seeing if they exist. As far as I recall, no newer guidelines exist. The Fukuoka guidelines are the most current issued by that working group.

REPLY

I wish I could attach some links. I spent a tremendous amount of time researching IPMNs about 8 to 12 months ago and I saved a lot of the links in an email folder. When you asked me to show you where I found the newest guidelines, I came across a lot of really good info that I had forgotten about. ..

REPLY
@stageivsurvivor

I too would be interested in the source of the new recommendations as I would like to read more in depth.

There is a clinical study underway at multiple sites around the USA that is sponsored by ECOG-ACRIN Cancer Group (Eastern Comprehensive Oncology Group-American College of Radiology Imaging Network). The study is EA2185 (https://ecog-acrin.org/clinical-trials/ea2185-pancreas-cancer-prevention/). The purpose is to evaluate two surveillance methods with the objective of which provides better information and a secondary objective of ensuring no patient undergoes an interventional procedure that is unnecessary.

Jump to this post

Fukuoka guidelines for IPMNs in 2017

REPLY
Please sign in or register to post a reply.